• Allos Therapeutics Inc., of Westminster, Colo., reported net Folotyn (pralatrexate) sales of $8.2 million in the third quarter, below analyst estimates of $10 million. Since its January launch for peripheral T-cell lymphoma, the drug has garnered $23.5 million in net sales. Allos reported a third-quarter net loss of $18.8 million, or 18 cents per share, which was narrower than the 20-cent-per-share loss analysts had expected. The biotech had $108.9 million in cash and equivalents as of Sept. 30. Shares (NASDAQ:ALTH) gained 60 cents, or 16 percent, to close at $4.34 on Friday.

• Amylin Pharmaceuticals Inc., of San Diego, reported third-quarter net product sales of $154 million. Sales of diabetes drug Symlin (pramlintide acetate) were $21.6 million while sales of diabetes drug Byetta (exenatide) came in at $132.4 million, in line with analyst expectations. Amylin reported a GAAP net loss for the quarter of $50.7 million, or 35 cents per share, and ended the quarter with $537.7 million in cash and equivalents. Investors remain focused on extended-release exenatide product Bydureon, which received a second complete response letter from the FDA last month. Shares (NASDAQ:AMLN) gained 36 cents, to close at $13.05 Friday. (See BioWorld Today, Oct. 21, 2010.)